James Fairlamb, MD
Cardiovascular Disease · Columbia, MONPI 1326029745
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $278,980 of the $341,812 with a category attached, or 81.6%. 30 manufacturers reported payments, led by Amgen at 38.6% of the total. Reporting peaked in 2019 at $85,075 and has fallen 87.8% since, to $10,397 in 2025. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 537 payments — averaging $636.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$132K
- Boehringer Ingelheim$71K
- Pfizer$50K
- Amarin Pharma, Inc.$40K
- Lilly USA, LLC$20K
- AstraZeneca$11K
- plus $18K from 24 others
Across 15 payments — averaging $2084.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$14K
- Sanofi US Services Inc.$12K
- Medtronic$5K
What the payments were for
- Consulting fees$5,1852%
- Speaking & faculty fees$278,98082%
- Travel & lodging$41,20312%
- Food & beverage$16,3525%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 157 | $132,012 |
| Boehringer Ingelheim | 69 | $71,321 |
| Pfizer | 53 | $49,861 |
| Amarin Pharma, Inc. | 60 | $39,795 |
| Lilly USA, LLC | 21 | $20,429 |
| AstraZeneca | 25 | $10,865 |
| Sanofi-aventis U.S. LLC | 5 | $5,471 |
| Novartis | 8 | $3,446 |
| Boston Scientific | 46 | $2,999 |
| Biotronik Inc. | 23 | $1,975 |
| Regeneron Healthcare Solutions, Inc. | 2 | $992 |
| E.r. Squibb & Sons, L.L.C. | 17 | $340 |
| Johnson & Johnson | 10 | $319 |
| Bayer | 4 | $255 |
| Cvrx, Inc. | 3 | $229 |
| Novo Nordisk | 7 | $221 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $205 |
| Medtronic | 2 | $194 |
| Alnylam Pharmaceuticals Inc. | 2 | $189 |
| Impulse Dynamics (USA) Inc. | 2 | $170 |
| Scpharmaceuticals Inc. | 1 | $108 |
| Edwards Lifesciences | 2 | $90 |
| Actelion Pharmaceuticals US, Inc. | 1 | $78 |
| Abbott | 4 | $73 |
| Sanofi | 3 | $58 |
| Merck | 2 | $51 |
| Abiomed | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Shockwave Medical, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$130,283
- JARDIANCE$90,362
- VYNDAQEL$45,911
- Vascepa$38,716
- FARXIGA$10,200
- PRALUENT$6,298
- ENTRESTO$3,360
- BioMonitor$483
- AMVIA EDGE$454
- PRADAXA$435
- BRILINTA$311
- OPTIMIZER$282
- Kerendia$226
- ONYX FRONTIER$147
- Barostim Neo System$128
- Watchman$125
- RHYTHMIA$121
- Corlanor$119
- XARELTO$118
- GENERAL - THERAPIES$117
How this compares
$341,812 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 826 | $789,843 |
| OzempicSemaglutide | 396 | $498,114 |
| JardianceEmpagliflozin | 381 | $404,359 |
| Repatha SureclickEvolocumab | 261 | $300,030 |
| VyndamaxTafamidis | 12 | $249,205 |
| EntrestoSacubitril/Valsartan | 201 | $248,367 |
| FarxigaDapagliflozin Propanediol | 250 | $235,163 |
| XareltoRivaroxaban | 176 | $185,879 |
| Praluent PenAlirocumab | 86 | $86,443 |
| WegovySemaglutide | 60 | $81,857 |
| MounjaroTirzepatide | 76 | $77,946 |
| VascepaIcosapent Ethyl | 48 | $34,652 |
| NexlizetBempedoic Acid/Ezetimibe | 36 | $26,825 |
| MultaqDronedarone Hcl | 24 | $18,292 |
| Bisoprolol Fumarate | 767 | $17,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $49,861 | $1,039,049838 claims |
| Novo NordiskOzempic, Wegovy | $221 | $579,971456 claims |
| Boehringer IngelheimJardiance, Pradaxa | $71,321 | $409,668405 claims |
| NovartisEntresto | $3,446 | $248,367201 claims |
| AstraZenecaFarxiga | $10,865 | $235,163250 claims |
| Johnson & JohnsonXarelto | $319 | $185,879176 claims |
| Lilly USA, LLCMounjaro | $20,429 | $77,94676 claims |
| Esperion Therapeutics, Inc.Nexlizet | $14 | $26,82536 claims |
| Sanofi-aventis U.S. LLCMultaq | $5,471 | $18,29224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Columbia
- Renee SullivanColumbia$18K
- Chirag BavishiColumbia$16K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James EllisonChesterfield$267K
- Osler Jay GuzonSaint Louis$211K
- Matthew FraleyFlorissant$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.